The Bull Case For NeoGenomics (NEO) Could Change Following RaDaR Assay Data and Technology Platform Advances

• In late October 2025, NeoGenomics showcased new research at the ISLB Annual Congress highlighting high concordance for its updated RaDaR® ST assay in molecular residual disease detection, alongside analytical validation of its PanTracer LBx liquid biopsy platform and several presentations on genomic profiling for solid tumor cancers.

• This suite of research presentations, paired with reaffirmed 2025 financial guidance and ongoing revenue growth despite wider net losses, points to continued advancement in both scientific innovation and commercial execution for the company.

• We’ll explore how NeoGenomics’ RaDaR assay performance and technology expansion may influence its long-term growth story in diagnostics.

These 12 companies survived and thrived after COVID and have the right ingredients to survive Trump’s tariffs. Discover why before your portfolio feels the trade war pinch.

Being a shareholder in NeoGenomics today is about believing in the company’s ability to deliver on the promise of next-generation oncology diagnostics, driven by its liquid biopsy and molecular residual disease technology. The recent research presentations, which confirmed the consistent test performance of its RaDaR ST assay and highlighted progress with PanTracer, directly support innovation and potential product differentiation, but they do not materially ease near-term concerns around rising net losses, which remain a key risk to the business.

Among the latest announcements, NeoGenomics’ reaffirmed 2025 revenue guidance stands out as most relevant here, particularly as it was issued alongside these scientific milestones. While the strong research results may position the company well in diagnostics, the ongoing guidance reflects that financial unpredictability, stemming from persistent net losses and expense pressures, remains the most important short-term factor for investors watching the stock.

On the other hand, it’s important for investors to be aware that rising innovation alone may not offset…

Read the full narrative on NeoGenomics (it’s free!)

NeoGenomics’ outlook anticipates $893.1 million in revenue and $48.1 million in earnings by 2028. This requires 9.0% annual revenue growth and a $152.1 million increase in earnings from the current -$104.0 million.

Uncover how NeoGenomics’ forecasts yield a $11.72 fair value, a 16% upside to its current price.

Simply Wall St Community fair value estimates for NeoGenomics range widely, from US$10.20 to US$19.00 across 3 perspectives. While optimism around future diagnostic growth is clear, persistent net losses continue to weigh on company performance and outlook.

Explore 3 other fair value estimates on NeoGenomics – why the stock might be worth just $10.20!

Disagree with existing narratives? Create your own in under 3 minutes – extraordinary investment returns rarely come from following the herd.

Every day counts. These free picks are already gaining attention. See them before the crowd does:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NEO.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]